You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
WYE 687 dihydrochloride
Biological Activity for WYE 687 dihydrochloride
WYE 687 dihydrochloride is a potent, ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) (IC50 = 7 nM). Displays selectivity for mTOR over PI 3-Kα (~100-fold) and PI 3-Kγ (~500-fold). Inhibits phosphorylation of mTORC1 and mTORC2 substrates including S6K, SGK and Akt; blocks VEGF secretion and HIF-1α expression. Exhibits antiproliferative effects in cancer cell lines through G1 cell cycle arrest and selective apoptosis.
Sold for research purposes under agreement from Pfizer Inc.
Compound Libraries for WYE 687 dihydrochloride
Technical Data for WYE 687 dihydrochloride
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for WYE 687 dihydrochloride
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for WYE 687 dihydrochloride
The following data is based on the product molecular weight 601.53. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.66 mL||8.31 mL||16.62 mL|
|5 mM||0.33 mL||1.66 mL||3.32 mL|
|10 mM||0.17 mL||0.83 mL||1.66 mL|
|50 mM||0.03 mL||0.17 mL||0.33 mL|
Product Datasheets for WYE 687 dihydrochloride
References for WYE 687 dihydrochloride
References are publications that support the biological activity of the product.
Yu et al (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer.Res. 69 6232 PMID: 19584280
If you know of a relevant reference for WYE 687 dihydrochloride, please let us know.
View Related Products by Product Action
Keywords: WYE 687 dihydrochloride, WYE 687 dihydrochloride supplier, mTOR, WYE687, mammalian, target, rapamycin, inhibitors, inhibits, ATP, competitive, potent, selective, antiproliferatives, mTORC1, mTORC2, S6K, SGk, Akt, blocks, VEGF, secretion, HIF-1alpha, HIF-1a, antiproliferative, cell, cycle, arrest, apoptosis, Cell, Cycle, Inhibitors, 4282, Tocris Bioscience
1 Citation for WYE 687 dihydrochloride
Citations are publications that use Tocris products. Selected citations for WYE 687 dihydrochloride include:
Saric et al (2016) mTOR controls lysosome tubulation and antigen presentation in macrophages and dendritic cells. Data Brief 27 321 PMID: 26582390
Do you know of a great paper that uses WYE 687 dihydrochloride from Tocris? Please let us know.
Reviews for WYE 687 dihydrochloride
There are currently no reviews for this product. Be the first to review WYE 687 dihydrochloride and earn rewards!
Have you used WYE 687 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Metabolism Research Product GuideNew
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
- Tricarboxylic Acid Cycle
- 1C Metabolism and Nucleic Acid Synthesis
- Drivers of Metabolic Reprogramming
- pH and Redox Balance
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.